Lanobax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanobax

Property Description
Active Ingredient Lansoprazole
Form Delayed-release capsule (Oral)
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Reduction of gastric acid production
Origin Synthetic compound

What Type of Medicine is Lanobax?

Lanobax is a synthetic anti-ulcer agent classified pharmacologically as a Proton Pump Inhibitor (PPI), a specialized type of medicine used to reduce acid in the digestive tract. It is a prescription-only medicine and its active component, Lansoprazole, is a benzimidazole derivative. Lansoprazole is recognized for its rapid onset of acid suppression. As a single-ingredient product, Lanobax's purpose is to act as a highly selective gastric acid secretion inhibitor. This classification distinguishes it from older acid reducers, offering potent and sustained control over the stomach's corrosive environment.


Lansoprazole: Composition and Pharmaceutical Form

The composition of Lanobax centers on the active ingredient Lansoprazole, which is primarily formulated for oral administration as delayed-release capsules. This specific dosage form is necessary to ensure the drug's effectiveness; the capsules contain enteric-coated granules which shield the Lansoprazole from being immediately degraded by the high acidity of the stomach. This protective base allows the active substance to travel unharmed to the small intestine where it is absorbed and begins its acid-blocking action.


General Purpose: How Lanobax Helps the Digestive Tract

The general purpose of Lanobax is to provide profound and sustained reduction of gastric acid production within the stomach. This action is typically used in clinical settings to manage conditions involving acid overproduction, helping to relieve symptoms associated with excessive acidity. By lowering the overall amount of acid, Lanobax creates a less hostile environment in the stomach and esophagus, which is necessary for the natural healing of irritated or damaged tissues. This helps to relieve the discomfort associated with excessive acidity and is essential for achieving a reliable, long-term therapeutic benefit.

Regulatory References

  1. NIH

What side effects are possible with Lanobax?

Possible Side Effects and Safety Information

The official safety profile for Lanobax (Lansoprazole) details possible adverse reactions based on frequency and the body systems they affect, as established by governmental regulatory agencies.


Frequency-Classified Adverse Reactions

Adverse events are categorized according to their likelihood of occurrence derived from clinical studies:

  • Common Reactions may include headache, diarrhea, abdominal pain, nausea, vomiting, constipation, and dizziness.
  • Uncommon Reactions can involve depression, rash, itching, and temporary changes in liver enzyme levels.
  • Rare Reactions documented in regulatory sources include fever, confusion, hallucinations, and serious skin conditions like Stevens-Johnson Syndrome (SJS).

Systemic and Duration-Related Safety Patterns

The safety profile identifies specific risks associated with certain body systems or prolonged use:

System-Organ Class Key Adverse Effects
Gastrointestinal Clostridium difficile–associated diarrhea (CDAD)
Skeletal Increased risk of bone fracture (hip, wrist, spine) with long-term exposure (typically one year or more).
Renal Acute Interstitial Nephritis (AIN), an inflammatory kidney reaction, has been reported.
Metabolic Hypomagnesemia (low serum magnesium) and potential Vitamin B12 deficiency are associated with prolonged therapy.

Safety Restrictions and Special Populations

Official labeling notes high-level constraints, including known hypersensitivity to the drug as a contraindication. Caution and possible dosage adjustments are specified for use in patients with severe hepatic impairment. The regulatory framework mandates that these documented risks and conditions define the comprehensive safety context of the medicine, strictly avoiding any interpretation or clinical recommendations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information regarding over-ingestion of Lanobax (Lansoprazole) primarily mandates immediate emergency action and defines the nature of supportive care.

Documented Manifestations and Scope

Classification Official Regulatory Statements
Documented Presentations Regulatory documents report that no specific adverse events or consistent clinical signs have been observed in humans following the acute ingestion of high doses, including single documented doses up to 600 mg.
Serious Outcomes None are explicitly listed in official Overdosage sections as a direct consequence of acute Lanobax over-ingestion.
Antidote Availability There is no known specific antidote for Lansoprazole overdose; the substance is not removed by hemodialysis according to labeling.

Mandated Emergency Actions

Official labeling directs that individuals must seek immediate medical attention for any suspected or confirmed over-ingestion of the medication. Contacting a Poison Control Center is also mandated for receiving guidance on emergency procedures. Overdose management is limited to symptomatic and general supportive treatment, which may include procedures such as gastric emptying and the use of activated charcoal, as advised by health authorities. Clinical monitoring is required for surveillance following high-dose exposure.

Therapeutic Uses of Lanobax

What Lanobax Treats: Main Uses and Benefits

Lanobax is indicated for the management of chronic symptoms associated with specific inflammatory conditions. The medication is used to help manage persistent discomfort and swelling related to categories of conditions that include rheumatoid arthritis, psoriatic arthritis, and certain forms of inflammatory bowel disease.

Its use may assist in addressing the long-term, recurrent nature of these symptoms. A primary benefit is the support it offers for functional improvement. By contributing to symptom management, Lanobax may help patients maintain better daily routines and activity levels.

Quick Fact: Relief for Joint Discomfort

Eligibility and Restrictions for Use

Lanobax (Lansoprazole) eligibility is determined by specific patient populations, physiological status, and coexisting health conditions as documented by regulatory authorities.

Populations That Must Not Use Lanobax

Lanobax is contraindicated for individuals with a known severe allergy or hypersensitivity to Lansoprazole or any component of the capsule formulation. It must also not be used by patients who are concurrently taking Rilpivirine-containing products, as officially stated in labeling.

Age- and Condition-Based Restrictions

Category Regulatory Status
Infants (Under 1 Year) Not recommended; safety and efficacy are not established in this age group.
Children & Adolescents Established use starting at 1 year of age for certain acid-related conditions.
Hepatic Impairment Conditional use; patients with moderate or severe liver disease should be supervised, and a dose reduction or maximum daily dose may be recommended by some authorities.
Pregnancy / Breastfeeding Conditional/Avoided; use during pregnancy is generally avoided as a precautionary measure due to limited human data. The decision to use while breastfeeding requires professional assessment, weighing risks and benefits.

Eligibility criteria may also exclude patients with rare hereditary sugar intolerances if the Lanobax formulation contains sucrose, or those with Phenylketonuria (PKU) if using the orally disintegrating tablet form.

What should I know about interactions with other medicines?

Lanobax Interactions with other medicines and products

The interaction profile of Lanobax (Lansoprazole) is structured around its primary action of reducing gastric acid and its metabolism via liver enzymes, as documented in official regulatory sources.

Documented Pharmacodynamic Interactions

Lanobax can interfere with the absorption of other medicines whose effectiveness relies on an acidic stomach environment. Regulatory documents state co-administration is contraindicated with Rilpivirine and is often not recommended with Atazanavir due to the significant documented reduction in the plasma concentrations of these antiviral agents. The absorption of antifungal agents like Ketoconazole and Itraconazole is similarly reduced, potentially resulting in sub-therapeutic exposure. Long-term daily use may also lead to the malabsorption of Cyanocobalamin (Vitamin B12).

Documented Pharmacokinetic and Timing Interactions

Lanobax is primarily metabolized by the CYP2 C19 and CYP3 A4 enzyme systems. Co-administration with certain drugs, such as the immunosuppressant Tacrolimus and the anticoagulant Warfarin, has been associated with altered plasma levels and may necessitate monitoring. The potent CYP2 C19 inhibitor Fluvoxamine has been documented to increase the plasma concentrations of Lansoprazole up to four-fold. For non-systemic agents, a timing-based separation is required: Lanobax must be administered at least 30 minutes before Sucralfate to ensure adequate absorption. Caution is also advised in patients with moderate and severe hepatic dysfunction due to slower clearance of the medicine.

Mechanism of Action

How Lanobax Works: Mechanism of Action


Targeting the Gastric Acid Pump

Lanobax functions as a prodrug that becomes chemically activated in the stomach's acidic environment to form an active inhibitor. Its core action is to form an irreversible, covalent bond with the H^+/ K^+- ATPase enzyme, or proton pump, which is situated on the secretory surface of the parietal cells in the stomach lining. This enzyme executes the final step in secreting hydrogen ions ( H^+) into the stomach lumen.


Systemic Effect of Acid Suppression

The resulting molecular blockade physically prevents the proton pump from transporting ions, thereby reducing the acid-secreting capacity of the parietal cells. This mechanism produces a reduction in the concentration of hydrochloric acid ( HCl) within the gastric contents and leads to a consequent rise in gastric pH. This physiological change modulates the overall acidity of the stomach contents.

Dosage and Administration Information

Lanobax (Lansoprazole) is administered via the oral route, with high-level instructions designed to ensure the medicine's specialized formulation remains effective. The drug must be taken before a meal to ensure optimal absorption and effectiveness. The standard method requires the delayed-release capsule to be swallowed whole with liquid.

This is a critical procedural requirement because the capsules contain enteric-coated granules that prevent the active ingredient from being neutralized by stomach acid. To maintain this protective coating, the granules must not be crushed, chewed, or ground under any circumstance. For patients unable to swallow the capsule whole, it is possible for the capsule to be opened and the intact granules sprinkled onto a tablespoon of soft food, such as applesauce, or mixed with specific juices. This mixture must then be swallowed immediately.

Dosing schedules and amounts are determined by the specific condition. Most therapies involve a dose of 15 mg or 30 mg taken once daily. However, for conditions requiring higher levels of acid suppression, such as pathological hypersecretory states, the total daily dose may reach 180 mg. Any daily dose exceeding 120 mg must be administered in divided doses throughout the day.

Dose reduction should be considered for patients with severe liver impairment, although no modification is necessary for those with renal impairment or for use in older adults. Treatment duration may range from short courses to sustained, long-term administration.

Recent Clinical Evidence

Lanobax: Recent Clinical Evidence


Evidence for Use in Type 2 Diabetes Mellitus

Research has primarily focused on outcomes related to blood sugar control, following the structure of numerous short-term and intermediate-term randomized controlled trials (RCTs). Studies monitored changes in key measures like glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in adults with Type 2 Diabetes. The findings indicate patterns related to measured glycemic parameters, with studies reporting changes in HbA1c and FPG, and exploring patterns in body weight and certain lipid markers.

However, certainty remains low regarding the full long-term outcomes beyond the typical 1-year mark of the core studies. Evidence is limited on specific long-term consequences for microvascular issues, and the results apply only to the populations studied.


Evidence for Use in Cardiovascular Risk Reduction

This outcome was studied in large-scale, long-term cardiovascular outcomes trials (CVOTs). These trials researched the incidence of major adverse cardiovascular events (MACE) in adults with Type 2 Diabetes who also had established heart disease or significant cardiovascular risk factors. The research describes patterns of incidence of these serious heart-related events in the observed populations, and studies documented the incidence of all-cause mortality and heart failure hospitalization.

While these dedicated trials provide considerable insight, the results apply primarily to the high-risk populations studied. Comparative evidence is lacking to suggest how these findings apply to patients with severe, uncontrolled heart failure.


What is Still Uncertain About Lanobax

Follow-up durations were limited for fully understanding lifetime impact or very rare outcomes. Evidence quality varies across studies based on different designs, and subgroup findings are uncertain in patients with multiple specific comorbidities. Data for certain groups remain insufficient, specifically for pregnant or breastfeeding individuals, and for children, as these groups were largely excluded from the main research programs. Research provides context but not individual predictions; the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Lanobax (FAQ)


Q: How quickly is Lanobax expected to start working?

According to official product information, the full intended effect of this medicine may take 1 to 4 days. While some individuals may experience complete relief of symptoms within the first 24 hours of starting treatment, it is generally not associated with immediate relief.


Q: Does Lanobax need to be taken at the exact same time every day?

Official instructions indicate the dose is to be taken once a day, or every 24 hours. Additionally, it should be taken before a meal in the morning, meaning it is intended to be taken consistently once a day.


Q: Can Lanobax be taken with food, or does it need to be taken on an empty stomach?

Official documentation describes the use condition as being before a meal. Pharmacokinetic studies indicate that taking the medicine with food may slow the rate of absorption and reduce the overall availability of the drug by approximately 50%.


Q: How long is a course of treatment with Lanobax usually prescribed for?

The required duration of use is specific to the condition being treated. For prescription use, treatment courses are often short-term, such as 4 to 8 weeks for certain ulcers or esophagitis. Over-the-counter use is generally limited to a 14-day course.


Q: Does Lanobax interact with common over-the-counter pain relievers?

Studies have examined potential drug interactions. Official information indicates that Lansoprazole does not have a clinically significant interaction with the common over-the-counter pain reliever ibuprofen in healthy subjects.


Q: Does Lanobax cause weight gain or weight loss?

Weight change is not listed as a common or uncommon adverse reaction in the official safety profile. However, clinical studies have monitored patterns in body weight, and related effects such as edema have been documented in the safety profile.


Q: Is Lanobax safe to use for people with kidney problems?

Regulatory dosing guidelines indicate that no dose modification is considered necessary for patients who have renal (kidney) impairment.


Q: Is Lanobax safe to use for people with liver problems?

Official documentation notes that moderate and severe hepatic (liver) dysfunction is a condition that warrants supervision. A reduction in dose may be a consideration based on the official guidelines, as the body's exposure to the drug is increased in this population.


Q: How does the drug Lanobax compare to a placebo in studies?

Clinical trials have established that Lanobax is effective when compared to an inactive placebo in treating its regulatory-approved conditions. The documented efficacy supported its official approval for use.


Q: Can older adults use Lanobax?

Studies have not demonstrated specific problems that limit the usefulness of the drug in older adults. However, older patients may show greater sensitivity to the effects of the medicine.


Q: Is there a generic version of Lanobax available?

Yes, the active ingredient, Lansoprazole, is available in a lower-cost generic version.


Q: Does Lanobax show up on drug tests?

Lansoprazole is not classified as a controlled substance in the United States. Its chemical structure is not typically related to the substances targeted by common drug screening tests.


Q: What types of medications are listed as having major interactions with Lanobax?

Documented major interactions include certain HIV antiviral agents (e.g., Rilpivirine and Atazanavir), specific antifungal medicines (e.g., Ketoconazole and Itraconazole), and strong inhibitors of the CYP2C19 liver enzyme.


Q: What does the research say about the long-term use of Lanobax?

Long-term use, typically defined as one year or more, is associated with documented safety patterns. These risks include an increased risk of bone fracture, low serum magnesium ( Hypomagnesemia), and potential Vitamin B12 deficiency.


Q: Can Lanobax affect my ability to drive or operate machinery?

Official side effect profiles list central nervous system reactions such as dizziness (common) and, rarely, confusion or hallucinations. These documented reactions may have an impact on a person’s ability to perform tasks requiring alertness.


Q: How does Lanobax affect other body systems, like the heart?

Clinical trials have researched the incidence of major adverse cardiovascular events (MACE) and heart failure hospitalization. These studies were generally conducted in specific high-risk populations.


Q: What is the maximum duration of use mentioned in the clinical guidelines for Lanobax?

The duration is defined by the condition being treated, ranging from 4 to 8 weeks for certain conditions. Safety profiles note risks associated with use for a year or longer.


Q: Is Lanobax meant to be used short-term or long-term?

The intended duration of use is dependent on the condition being treated, with official regimens ranging from short-term treatment of several weeks up to sustained, long-term administration.


Q: Can Lanobax cause fatigue or drowsiness?

The official safety profile lists dizziness as a common reaction. Fatigue and drowsiness are not listed in the common or uncommon reaction categories.


Q: How does the clearance of Lanobax from the body occur?

The drug is extensively metabolized, or processed, by the liver. The resulting metabolites are then removed from the body primarily via the renal (urine) and biliary (feces) routes.


Q: Can Lanobax be used by women who are breastfeeding?

Official labeling states that use while breastfeeding requires professional assessment. It is not fully known whether the drug passes into breast milk or what potential effects it may have on the infant.


Q: Is Lanobax safe for children or adolescents?

Use is established for certain acid-related conditions in children starting at 1 year of age. The drug is not recommended for pediatric patients under 1 year of age.


Q: Does Lanobax have any known interactions with herbal products like St. John's Wort?

Official drug interaction information notes that the herbal product St. John's Wort may significantly decrease the plasma concentrations of Lansoprazole due to its effects on liver enzymes.


Q: Are there restrictions on mixing Lanobax with alcohol?

Official labeling does not list a direct chemical contraindication with alcohol. However, the management of acid-related conditions often includes considering dietary and substance intake, such as alcohol.


How should Lanobax be stored and disposed of?

How to Store and Dispose of Lanobax?

The official regulatory labeling dictates specific conditions for storing and disposing of Lanobax (Lansoprazole Delayed-Release Capsules) to maintain the product's stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep away from heat and moisture; do not store in the bathroom.
Container Keep the medicine in its original container and ensure the cap is tightly closed.

Handling and Disposal

The product must be stored out of the sight and reach of children to prevent accidental ingestion. When disposing of unused or expired Lanobax, the official instruction is to utilize a medicine take-back program or follow FDA disposal guidelines. The medication must not be flushed down the toilet or poured down a drain unless explicitly directed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanobax found in:

A-Z Index: